Nasybullina N M, Gunar V I, Zherdev V P, Sariev A K, Kozlova G S, Mirzoian R S, Gan'shina T S, Karaev A L
Eksp Klin Farmakol. 1997 Mar-Apr;60(2):58-61.
The permeability through the blood-brain barrier of N-(4-hydroxy-3,3 dimethyl-2-oxo-1-butiryl) gamma-aminobutyric acid calcium salt, a new neurotropic drug calcium ketohomopantothenate (KPA-Ca), was studied in comparison with that of calcium homopantothenate, pantogam (P) Liquid chromatography analysis showed that after oral administration of KPA-Ca and P both forms of these agents, namely, oxy- and keto- derivatives of homopantothenic acid, were found in the brain of experimental rats, the KPA-Ca (ketoform) content being higher. Pharmacological studies showed that KPA-Ca penetrates the blood-brain barrier in greater amounts and causes a higher effect on the rate of cerebral blood flow when it is administered per os in a dose of 50 mg/kg.
研究了新型神经营养药物酮基泛酸钙(KPA-Ca)与泛酸钙(Pantogam,P)相比透过血脑屏障的通透性。液相色谱分析表明,给实验大鼠口服KPA-Ca和P后,在其脑内均发现了这两种药物的两种形式,即泛酸的氧代和酮代衍生物,其中KPA-Ca(酮形式)的含量更高。药理学研究表明,当以50mg/kg的剂量口服给药时,KPA-Ca能以更大的量穿透血脑屏障,并对脑血流速率产生更高的影响。